Doctor of Philosophy

ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy

Retrieved on: 
Wednesday, June 29, 2022 - 9:05pm

An estimated three million Americans have epilepsy, and 25 to 35 percent live with ongoing seizures despite dozens of approved drugs on the market.

Key Points: 
  • An estimated three million Americans have epilepsy, and 25 to 35 percent live with ongoing seizures despite dozens of approved drugs on the market.
  • The first stage of the trial is an open-label dose-escalation study in up to 10 patients with MTLE.
  • Our team is proud to partner with Neurona to support their Phase 1/2 clinical trial of what could potentially be a breakthrough regenerative cell therapy for MTLE.
  • ClearPoint Neuro is partnered with approximately 45 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.

Life Edit Therapeutics Appoints Joy A. Cavagnaro to Its Scientific Advisory Board

Retrieved on: 
Wednesday, June 29, 2022 - 9:30pm

Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB).

Key Points: 
  • Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB).
  • We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics, said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio.
  • Joys expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases.
  • About Life Edit Therapeutics Inc.
    Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the worlds largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors.

Allarity Therapeutics Announces Executive Leadership Transition

Retrieved on: 
Wednesday, June 29, 2022 - 9:01pm

Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer,

Key Points: 
  • Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer,
    Cambridge, MA, U.S.A. (June 29, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced an executive leadership transition.
  • Effective immediately, the Companys Board of Directors has appointed James G. Cullem, J.D., current Chief Business Officer, as interim Chief Executive Officer (CEO) and Joan Y.
  • During his tenure with Allarity, Mr. Cullem has been responsible for the identification and acquisition of most of the Companys lead clinical oncology assets.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Scientists Look to the Sky in Effort To Mitigate Carbon Problem

Retrieved on: 
Wednesday, June 29, 2022 - 4:43pm

The article, which appears in the journal Nature Communications, provides a first evaluation of the technologies environmental trade-offs over a long-term planning horizon.

Key Points: 
  • The article, which appears in the journal Nature Communications, provides a first evaluation of the technologies environmental trade-offs over a long-term planning horizon.
  • They determined that a rapid decarbonization is required to increase the efficiency of DAC in removing carbon dioxide and to mitigate the effects of climate change.
  • The work by the NREL scientists was funded by the internal Laboratory Directed Research and Development program.
  • NREL is the U.S. Department of Energy's primary national laboratory for renewable energy and energy efficiency research and development.

Fujifilm Celebrates Four Recent Recipients of Fujifilm Fellowship at Harvard Medical School

Retrieved on: 
Wednesday, June 29, 2022 - 4:25pm

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced that four doctoral students have been awarded the Fujifilm Fellowship at Harvard Medical School (HMS).

Key Points: 
  • CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced that four doctoral students have been awarded the Fujifilm Fellowship at Harvard Medical School (HMS).
  • The mission of the program is to equip promising scientists with the specialized skills needed to translate their research findings into next-generation medical solutions for patients.
  • Specifically, the program awards two years of research funding to students from across the nine HMS-based life sciences Ph.D. programs.
  • The Fujifilm Fellowship program was designed by Fujifilm and HMS to advance translational medicine research by investing in the next-generation of scientists.

IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience Conference FENS Forum 2022

Retrieved on: 
Wednesday, June 29, 2022 - 4:18pm

The conference will take place in Paris, France, from July 9-13, 2022.

Key Points: 
  • The conference will take place in Paris, France, from July 9-13, 2022.
  • We are excited to release preclinical data for selective NKCC1-inhibitors from our neuroscience drug discovery initiative, which we believe has the potential to fundamentally redefine the therapeutic opportunities for children and adults with neurodevelopmental and cognitive disorders.
  • Details of the poster presentation are as follows:
    Title: Selective NKCC1 inhibitors for the treatment of Autism, Down syndrome, and brain disorders with defective neuronal Cl homeostasis.
  • This pathway is reported in Down syndrome, autism spectrum disorder, epilepsy, and other brain disorders characterized by increased intracellular chloride and depolarizing GABAergic transmission.

#PrideMonth: 8 LGBTQIA Key Opinion Leaders (KOLs) Making Big International Impact

Retrieved on: 
Wednesday, June 29, 2022 - 4:38pm

And who better to look up to than key opinion leaders (KOLs) who are making a big impact.

Key Points: 
  • And who better to look up to than key opinion leaders (KOLs) who are making a big impact.
  • Here is a list compiled by the Analytics firm KOLs (Key Opinion Leaders) of the top 8 LGBTQIA+ KOLs you should know about.
  • Diamond is one of the key opinion leaders (KOLs) attending this year's LGBTQ Health Conference.
  • As an expert in cofilin loss, Stefanie Elisabeth Windner is quickly becoming one of the top Key Opinion Leaders in this field.

Invited names Sherry Vidal-Brown Chief Human Resources Officer

Retrieved on: 
Wednesday, June 29, 2022 - 4:00pm

DALLAS, June 29, 2022 (GLOBE NEWSWIRE) -- Invited today, announced that Sherry Vidal-Brown will join the World Leader in Private Clubs as the Chief Human Resources Officer.

Key Points: 
  • DALLAS, June 29, 2022 (GLOBE NEWSWIRE) -- Invited today, announced that Sherry Vidal-Brown will join the World Leader in Private Clubs as the Chief Human Resources Officer.
  • She will oversee all aspects of the company's human resources function, including talent acquisition, training and development, total rewards, and internal communications.
  • Vidal-Brown brings more than 30 years of human resources experience.
  • Vidal-Brown comes to Invited from Caliber Collision, where she has served as Chief People and Communication Officer.

#PrideMonth: 8 LGBTQIA Key Opinion Leaders (KOLs) Making Big International Impact

Retrieved on: 
Wednesday, June 29, 2022 - 3:07pm

And who better to look up to than key opinion leaders (KOLs) who are making a big impact.

Key Points: 
  • And who better to look up to than key opinion leaders (KOLs) who are making a big impact.
  • Here is a list compiled by the Analytics firm KOLs (Key Opinion Leaders) of the top 8 LGBTQIA+ KOLs you should know about.
  • Diamond is one of the key opinion leaders (KOLs) attending this year's LGBTQ Health Conference.
  • As an expert in cofilin loss, Stefanie Elisabeth Windner is quickly becoming one of the top Key Opinion Leaders in this field.

#PrideMonth: 8 LGBTQIA Key Opinion Leaders (KOLs) Making Big International Impact

Retrieved on: 
Wednesday, June 29, 2022 - 3:07pm

And who better to look up to than key opinion leaders (KOLs) who are making a big impact.

Key Points: 
  • And who better to look up to than key opinion leaders (KOLs) who are making a big impact.
  • Here is a list compiled by the Analytics firm KOLs (Key Opinion Leaders) of the top 8 LGBTQIA+ KOLs you should know about.
  • Diamond is one of the key opinion leaders (KOLs) attending this year's LGBTQ Health Conference.
  • As an expert in cofilin loss, Stefanie Elisabeth Windner is quickly becoming one of the top Key Opinion Leaders in this field.